On September 14, 2026, Phio Pharmaceuticals announced the formal completion of its Phase 1b clinical study for PH-762 and submitted a comprehensive briefing package to the FDA. This submission supports the next phase of development in cutaneous squamous cell carcinoma and outlines plans for a Phase 2b neoadjuvant study. Clinical supplies for this upcoming trial are expected to be available in the first quarter of 2027, alongside final activities for nonclinical toxicology studies. Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing siRNA therapeutics using its INTASYL gene silencing technology to treat cancer.

Phio Pharmaceuticals Corp. reported financial results for the quarter ended June 30, 2026, on August 6, 2026. The company incurred a net loss of $4.1 million and held cash reserves of $13.0 million as of June 30, 2026. Research and development expenses rose to $3.1 million for the quarter, driven by increased nonclinical toxicology and CMC costs associated with its lead candidate PH-762. The company announced strategic advancements including the initiation of commercial scale active pharmaceutical ingredient production and a long-term non-clinical toxicology study expected to complete by year-end. Additionally, Phio plans to request an FDA meeting in Q3 2026 regarding next steps for PH-762 development and appointed Dr. R. Todd Plott M.D. to its Board of Directors. The company operates as a clinical-stage biopharmaceutical firm developing siRNA gene silencing therapeutics for cancer treatment.

Effective July 20, 2026, Phio Pharmaceuticals Corp. increased its Board of Directors to six members and appointed R. Todd Plott, M.D. to the Board and the Governance Committee. Dr. Plott is a board-certified dermatologist and former FDA advisory committee member with over 30 years of experience, intended to support the advancement of PH-762 for squamous cell carcinoma. He will receive standard non-employee director compensation and equity awards. The company is a clinical-stage biopharmaceutical company developing siRNA therapeutics using INTASYL technology to treat cancer.